title: Comparison by carcinoembryonic antigen doubling time of hepatic injection and infusion for unresectable hepatic metastasis from colorectal cancer.
abstract: This study explored the efficacy of hepatic arterial therapy, comparing both injection and infusion of 5-fluorouracil (5-FU) in prolonging the survival of 92 patients with recurrent unresectable hepatic metastasis from colorectal cancer. With respect to pretreatment carcinoembryonic antigen doubling time (CEA-DT), 56 patients were treated with intra-arterial injection, and 36 with intra-arterial infusion. In 21 patients with a CEA-DT of less than 40 days, the cumulative survival of patients treated with arterial injection was significantly longer than that of patients treated with arterial infusion. In 45 patients with a CEA-DT of 40-80 days, the survival curves of patients did not differ from each other. Of the remaining 26 patients with a CEA-DT of more than 80 days, those treated using arterial infusion had an excellent prognosis, in contrast to those treated using arterial injection, with statistical significance. CEA-DT may be useful when choosing a chemotherapy regimen, and may help to accurately establish the prognosis of patients with unresectable hepatic metastasis from colorectal cancer.
authors.affiliation: Second Department of Surgery, Tokyo Medical and Dental University, Japan.
authors.forename: W
authors.initials: W
authors.lastname: Ichikawa
authors.forename: Z
authors.initials: Z
authors.lastname: Nihei
authors.forename: N
authors.initials: N
authors.lastname: Kawamura
authors.forename: S
authors.initials: S
authors.lastname: Sawai
authors.forename: T
authors.initials: T
authors.lastname: Miyanaga
authors.forename: R
authors.initials: R
authors.lastname: Hirayama
authors.forename: Y
authors.initials: Y
authors.lastname: Mishima
mesh_terms: D000328:Adult; D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage / Q000627:therapeutic use*; D002272:Carcinoembryonic Antigen / Q000032:analysis / Q000378:metabolism*; D003110:Colonic Neoplasms / Q000473:pathology*; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000627:therapeutic use*; D006499:Hepatic Artery; D006801:Humans; D015918:Infusion Pumps, Implantable; D007261:Infusions, Intra-Arterial; D007269:Injections, Intra-Arterial; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000556:secondary*; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy; D011379:Prognosis; D012004:Rectal Neoplasms / Q000473:pathology*; D012074:Remission Induction; D015996:Survival Rate
chemical_list: D000964:Antimetabolites, Antineoplastic; D002272:Carcinoembryonic Antigen; D005472:Fluorouracil